Reproductive · Year 2 · from Reproductive
Case 3: Premature Ovarian Insufficiency
Clinical Image
Source: Wikipedia - Premature ovarian failure - CC BY-SA 4.0
Case Presentation
A 32-year-old woman presents with 8 months of amenorrhea after previously regular menstrual cycles. She also reports hot flashes, vaginal dryness, and difficulty concentrating. She and her husband have been trying to conceive for the past year without success. She has no history of chemotherapy, radiation, or ovarian surgery. There is a family history of a maternal aunt who went through menopause at age 35 and a cousin with intellectual disability. Physical examination reveals no goiter and normal secondary sexual characteristics. Laboratory studies show FSH 65 mIU/mL (elevated), estradiol 18 pg/mL (low), and negative pregnancy test. TSH is normal. A repeat FSH one month later is 58 mIU/mL, confirming the diagnosis of premature ovarian insufficiency (POI). Given the family history suggesting possible fragile X syndrome, FMR1 gene testing is performed and reveals she is a fragile X premutation carrier (75 CGG repeats). Karyotype is 46,XX. She is counseled about the genetic implications for herself (risk of fragile X-associated tremor/ataxia syndrome) and for family members. Regarding fertility, she is counseled that while spontaneous ovulation may occur intermittently in 5-10% of women with POI, her best option for pregnancy is donor egg IVF. She is started on hormone replacement therapy with transdermal estradiol plus cyclic oral progesterone, which she should continue until at least age 51 to prevent osteoporosis, cardiovascular disease, and urogenital atrophy associated with premature estrogen deficiency.
Key Learning Points
- Premature ovarian insufficiency (POI) is defined as ovarian failure before age 40, affecting approximately 1% of women; diagnosis requires two elevated FSH levels (>25-40 mIU/mL) measured at least one month apart
- All women with POI should be tested for FMR1 gene (fragile X premutation), which causes 2-5% of POI cases and has implications for family members at risk for fragile X syndrome
- Hormone replacement therapy is strongly recommended until the average age of natural menopause (51 years) to prevent long-term consequences of estrogen deficiency including osteoporosis, cardiovascular disease, and cognitive decline
- Unlike natural menopause, HRT in young women with POI represents physiologic replacement rather than pharmacologic therapy, and the risks associated with HT in older women do not apply